2026年11月4日星期三
M
Weltübersicht
Globale Kurznachrichten
Japan, South Korea stocks fall over 4% as Democrats lead in US midterms— 日经 Nikkei AsiaUS midterms live: Democrats flip Texas, near Senate control— 日经 Nikkei AsiaPetrovietnam CEO sees a future of nuclear and wind power— 日经 Nikkei AsiaTaiwan airlines continue flights over Russia, rattling Europeans— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan, South Korea stocks fall over 4% as Democrats lead in US midterms— 日经 Nikkei AsiaUS midterms live: Democrats flip Texas, near Senate control— 日经 Nikkei AsiaPetrovietnam CEO sees a future of nuclear and wind power— 日经 Nikkei AsiaTaiwan airlines continue flights over Russia, rattling Europeans— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei Asia

[Comment] Mitapivat in the RISE UP trial: a new therapy for sickle cell disease

Quelle 柳叶刀 LancetVor 11 Tagen
Inhaltszusammenfassung

Sickle cell disease is the most common haemoglobinopathy, affecting more than 7 million people worldwide.1 Despite substantial morbidity and mortality, access…

Diese Website bietet nur Titel- und Zusammenfassungsindexe. Der vollständige Inhalt und das Urheberrecht liegen beim ursprünglichen Herausgeber. Bitte klicken Sie auf den Original-Link, um ihn zu lesen.

Zum Originaltext
Zugehöriger Kanal
Gesundheit
Zugehörige Region
Vereinigtes Königreich
Originalsprache
English
Eintragsnummer
health-7abf72c7

Comments 0 comments

No comments yet. Be the first.

[Comment] Mitapivat in the RISE UP trial: a new therapy for sickle cell disease · Weltübersicht